Valneva (NASDAQ:VALN) Rating Lowered to Hold at Kepler Capital Markets

Kepler Capital Markets lowered shares of Valneva (NASDAQ:VALNGet Rating) from a buy rating to a hold rating in a report released on Thursday, The Fly reports.

Valneva Stock Performance

NASDAQ VALN opened at $20.24 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.50. Valneva has a 1 year low of $13.71 and a 1 year high of $67.84. The company has a fifty day moving average of $21.78 and a two-hundred day moving average of $28.71.

Valneva (NASDAQ:VALNGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.38. The company had revenue of $24.51 million during the quarter, compared to analyst estimates of $22.51 million. On average, equities analysts anticipate that Valneva will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC boosted its stake in shares of Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after buying an additional 7,664 shares during the period. Bank of America Corp DE acquired a new stake in shares of Valneva during the first quarter worth about $858,000. Finally, Alps Advisors Inc. acquired a new stake in shares of Valneva during the fourth quarter worth about $3,369,000. Institutional investors and hedge funds own 0.21% of the company’s stock.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Featured Stories

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with's FREE daily email newsletter.